AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
By Eleanor Laise
Drugmaker raises full-year profit outlook even as Humira sales continue to slide
AbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of blockbuster autoimmune drug Humira continued to fall amid new, lower-cost competition.
The drugmaker reported first-quarter net income of $1.369 billion, or 77 cents per share, versus $239 million, or 13 cents per share, in the year-earlier period. Adjusted earnings per share of $2.31, versus $2.46 a year earlier, beat the FactSet consensus of $2.26. Revenues totaled $12.31 billion in the quarter, up 0.7% from a year earlier, to beat the FactSet consensus of $11.93 billion.
AbbVie raised its full-year profit guidance. The company now expects 2024 adjusted earnings per share in the range of $11.13 to $11.33, up from previous guidance of $10.97 to $11.17.
Humira, which is facing new biosimilar competition, generated sales of $2.27 billion in the quarter - down nearly 36% from a year earlier, but still ahead of the FactSet consensus of $2.221 billion.
Total sales of AbbVie's immunology products came to $5.371 billion, down 3.9% from a year earlier, due to the Humira biosimilar competition, the company said.
First-quarter sales of arthritis drugs Skyrizi and Rinvoq helped cushion Humira's fall. Sales of both drugs came in above FactSet consensus estimates, as Skyrizi revenues jumped 48% from a year earlier and Rinvoq sales climbed 59%.
Sales of cancer drug Imbruvica fell 4.5% from a year earlier, to $838 million.
Qulipta, which last year got Food and Drug Administration approval as a migraine treatment, generated $131 million in sales, up 98% from a year earlier.
Sales from AbbVie's aesthetics business were down 4% from a year earlier, to $1.249 billion, amid declining sales of cosmetic Botox and the dermal filler Juvederm.
AbbVie shares (ABBV) have gained 8% in the year to date, while the S&P 500 is up 5.8%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-26-24 0736ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now